Long-term effect of losartan on kidney disease in American Indians with type 2 diabetes: A follow-up analysis of a randomized clinical trial

Diabetes Care

Volumn 39, Issue 11, 2016, Pages 2004-2010

  Tanamas, Stephanie K ^a   Saulnier, Pierre Jean ^a,b   Fufaa, Gudeta D ^a   Wheelock, Kevin M ^a   Weil, E Jennifer ^a   Hanson, Robert L ^a   Knowler, William C ^a   Bennett, Peter H ^a   Nelson, Robert G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN POTASSIUM; PLACEBO; RENIN INHIBITOR; ALBUMINOID; CREATININE; LOSARTAN;

ADULT; AGE DISTRIBUTION; AMERICAN INDIAN; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; EARLY INTERVENTION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ETHNOLOGY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; URINE;

ADULT; ALBUMINS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INDIANS, NORTH AMERICAN; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TIME; TREATMENT OUTCOME;

EID: 84994384417     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0795     Document Type: Conference Paper

References (25)

1. de Boer IH, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-2376
2. Nathan DM, Bayless M, Cleary P, et al.; DCCT/EDIC Research Group. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes 2013;62:3976-3986
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
4. Volpe M, Cosentino F, Tocci G, Palano F, Paneni F. Antihypertensive therapy in diabetes: The legacy effect and RAAS blockade. Curr Hypertens Rep 1022;13:318-324
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
6. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576
7. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013;62:3224-3231
8. Bennett PH, Burch TA, Miller M. Diabetes mellitus in American (Pima) Indians. Lancet 1971;2:125-128
9. Fufaa GD, Weil EJ, Lemley KV, et al. Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes. Clin J Am Soc Nephrol 2016;11:254-261
10. Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Tech Bull RegistMed Technol 1960;30:207-212
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329: 1456-1462
12. Brenner BM, CooperME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
13. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
14. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patientswith Type 2 Diabetes andMicroalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878
15. Maschio G, Alberti D, Janin G, et al.; The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945
16. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80:282-287
17. Hellemons ME, Persson F, Bakker SJ, et al. initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: A post hoc analysis of the IRMA-2 trial. Diabetes Care 2011;34: 2078-2083
18. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-886
19. Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc 2014;3:e000810
20. TobinMD, SheehanNA, ScurrahKJ,BurtonPR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. StatMed 2005;24:2911-2935
21. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S; HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112:1339-1346
22. Cherney DZ, Zinman B, Kennedy CR, et al. Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus. Kidney Int 2013;84:1246-1253
23. Pavkov ME, Hanson RL, Knowler WC, Bennett PH, Krakoff J, Nelson RG. Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 2007;30:1758-1763
24. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006;296:421-426
25. Pavkov ME, Bennett PH, Sievers ML, et al. Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes. Kidney Int 2005;68:1267-1274